Test Price
2,800 AED✅ Home Collection Available
ZFYVE27 Gene SPG33 Genetic Test – 2,800 AED
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Pre-Test Requirement: A genetic counselling session to draw a pedigree chart of family members affected with ZFYVE27 gene SPG33 is mandatory. Please call to schedule.
Test Overview & Methodology
This advanced next-generation sequencing test analyzes the entire ZFYVE27 gene to identify pathogenic variants causing Hereditary Spastic Paraplegia type 33 (SPG33), a progressive neurological disorder characterized by lower limb spasticity and weakness. DNA Labs UAE employs full-gene NGS with coverage of all exons and flanking splice sites to deliver definitive molecular diagnosis.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% analytical sensitivity | Variable, may miss deep intronic variants |
| Method | Full-gene NGS (all exons + splice sites) | Select exon amplification |
| Turnaround Time | 3 to 4 weeks | 6 to 8 weeks |
Specimen accepted: Blood, Extracted DNA, or One Drop Blood on FTA Card.
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“A positive ZFYVE27 result offers clarity after a often prolonged diagnostic journey, yet every identified variant must be carefully correlated with the patient’s clinical presentation. Genetic findings serve as a critical guide, but they do not replace the full clinical picture. Collaborative interpretation with a neurologist is essential for accurate treatment planning and family counselling.”
“Remember that a negative genetic result does not exclude all forms of hereditary spastic paraplegia. Continued clinical surveillance and follow-up remain paramount for optimal patient outcomes.”
Medication Advisory: Do Not Alter Prescribed Therapy Without Medical Consultation
⚠️ Medication Safety Warning
Never discontinue, adjust, or modify your prescribed anti-spastic, neuroprotective, or other medications solely based on genetic test results. Abrupt changes may cause rebound spasticity, increased fall risk, or other serious adverse events. Always consult your treating physician before making any treatment changes.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Recent allogeneic bone marrow or hematopoietic stem cell transplant (chimerism risk); active hematologic malignancy with circulating blasts.
- Exclusion: Unwillingness to provide a complete three-generation pedigree during the mandatory genetic counselling session.
- Emergency Red Flags: Sudden paralysis of any limb, acute visual loss, or new-onset seizures require immediate emergency department evaluation regardless of test status.
- Emergency Red Flags: Severe aspiration or breathing difficulty – call 998 immediately.
Patient FAQ & Clinical Guidance
1. What is the purpose of testing the ZFYVE27 gene, and who should consider it?
A: This test detects disease-causing mutations in the ZFYVE27 gene responsible for hereditary spastic paraplegia type 33 (SPG33). It is recommended for individuals with clinical symptoms such as progressive lower limb spasticity, weakness, and gait disturbance, especially when there is a family history suggestive of autosomal dominant inheritance. A confirmed molecular diagnosis guides prognosis, surveillance, and family planning.
2. How is the sample collected and is it painful?
A: Sample collection involves a standard venipuncture blood draw from the arm or a finger-prick onto an FTA card. Both methods involve minimal discomfort. Our certified phlebotomist uses a virtually painless technique, and the entire procedure is completed within minutes. Home collection is available daily from 8 AM to 11 PM via our temperature-controlled cold-chain logistics.
3. How long until I receive my results and what happens next?
A: Results are available within 3 to 4 weeks from sample receipt. You will receive a comprehensive molecular report, followed by a dedicated teleconsultation with our consultant medical geneticist to explain the findings, discuss clinical implications, and coordinate any necessary referrals to a neurologist for ongoing management.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Legal Compliance
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All patient genetic data are encrypted, processed, and stored in full compliance with the UAE PDPL. Genetic information is classified as sensitive personal data and is subject to the highest standards of confidentiality and access control.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: This test adheres to mandated quality controls and reporting standards for hereditary neurological conditions under UAE health information technology regulations.
Federal Decree-Law No. 4 of 2016 on Medical Liability: Patient safety and informed consent protocols follow federal standards for medical liability, ensuring that every test is accompanied by appropriate pre-test counselling and post-test clinical guidance.
ISO 9001:2015 Certified Facility | Corporate Lab: DNA Labs UAE
Clinical & Logistical Metadata
| Test Name | ZFYVE27 Gene SPG33 Genetic Test (Full Gene NGS Sequencing) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube), Extracted DNA (2 µg minimum, >50 ng/µL), or One Drop Blood on FTA Card. VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene analysis covering all coding exons and flanking splice sites, with >99.9% analytical sensitivity for single nucleotide variants and small indels. |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 94719-4 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians